- Roche announced the acquisition of multiplex molecular diagnostics testing company GenMark Diagnostics for $24.05/share in cash.
- Roche is getting very competitive multiplex molecular diagnostics testing capabilities, but also meaningful opportunities to improve margins/operating leverage, expand the test menu, and leverage its large global sales force.
- The buyout agreement is a win-win, giving Roche a leverageable testing platform and giving GenMark shareholders a healthy premium that values the technology and improvement/leverage potential.
For further details see:
GenMark Parlays Pandemic-Driven Momentum Into A Good Buyout Price